Entering text into the input field will update the search result below

Compugen's bispecific antibody derived from COM902 to enter clinical development

Aug. 19, 2021 7:56 AM ETCompugen Ltd. (CGEN) StockAZNBy: SA News Team
  • Compugen (NASDAQ:CGEN) announces that a bispecific antibody of AstraZeneca (NASDAQ:AZN) derived from COM902, CGEN's anti-TIGIT antibody, will advance into clinical development.
  • AstraZeneca plans to initiate a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small

Recommended For You

More Trending News

About CGEN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CGEN--
Compugen Ltd.